Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1Phase 1 1

Status

Terminated 5Completed 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 5Renal Insufficiency 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 882Bortezomib 481Lenalidomide 467Cyclophosphamide 367Melphalan 276Calcium Dobesilate 265daratumumab 241pomalidomide 216carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 70Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
melflufen × Plasma cell × Clear all
NCT03151811 2024-01-30

OCEAN

Oncopeptides AB

Phase 3 Terminated
495 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT04649060 2023-06-08

LIGHTHOUSE

Oncopeptides AB

Phase 3 Terminated
54 enrolled 21 charts
Plasma cell

Multiple Myeloma

NCT03639610 2023-03-10

BRIDGE

Oncopeptides AB

Phase 2 Terminated
35 enrolled 33 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT03481556 2022-12-19

ANCHOR

Oncopeptides AB

Phase 1/2 Terminated
56 enrolled 22 charts
Plasma cell

Multiple Myeloma

NCT02963493 2022-11-22

HORIZON

Oncopeptides AB

Phase 2 Completed
157 enrolled 26 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT04115956 2022-03-28

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Oncopeptides AB

Phase 1 Terminated
6 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡